To evaluate the relationship between dalbavancin exposure and clinical success in adults with complicated Staphylococcus aureus bacteremia.
Key Findings:
72 out of 93 evaluable patients (77%) achieved clinical success at day 70.
Patients with concentrations >32 μg/mL had a success rate of 97% compared to 68% for those with ≤32 μg/mL.
Higher AUC values were associated with improved outcomes, but did not reach statistical significance.
Interpretation:
The findings suggest a potential link between higher dalbavancin exposure and improved clinical outcomes, but causality cannot be established due to the observational nature of the analysis.
Limitations:
Exposure was not randomized, limiting causal inference.
Findings may not generalize to patients with early treatment failure or more severe illness.
Exploratory nature of exposure threshold definition increases risk of spurious findings.
Conclusion:
Sustained dalbavancin exposure may be important for preventing late complications of S aureus bacteremia, warranting further investigation into dosing strategies.
